|Bid||2.3800 x 800|
|Ask||2.4400 x 1800|
|Day's Range||2.3800 - 2.4752|
|52 Week Range||1.9000 - 6.2500|
|Beta (3Y Monthly)||1.35|
|PE Ratio (TTM)||1.07|
|Earnings Date||Mar 12, 2019 - Mar 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
HC2 Holdings (HCHC) delivered earnings and revenue surprises of 183.33% and 5.79%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Second Quarter 2019 Consolidated Net Revenue Grew 4.4% Year-Over-Year to $518.6 Million -- Reaffirms 2019 Guidance for Construction Segment - NEW YORK, Aug. 08, 2019 -- HC2.
HC2 Holdings (HCHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MediBeacon Inc., a St. Louis-based biotech developer, has reached a $30 million deal giving China's Huadong Medicine Co. Ltd. exclusive rights to MediBeacon's portfolio in China, Hong Kong, Macau and Taiwan.
MediBeacon and Huadong Medicine will collaboratively work to reach regulatory approval on MediBeacon's entire portfolio of assets in Greater China ST. LOUIS , July 31, 2019 /PRNewswire/ -- MediBeacon Inc ...
HC2 Holdings, Inc. (“HC2”) (HCHC), a diversified holding company announced today that MediBeacon Inc., a privately held portfolio company within HC2’s Pansend Life Science (“Pansend”) announced today that they have entered into a definitive agreement with Huadong Medicine, a publicly traded company on the Shenzhen Stock Exchange (SZ:000963, U.S. dollar equivalent $6 billion market cap). The agreement will provide exclusive rights to MediBeacon’s portfolio of assets in Greater China. Huadong Medicine will be responsible to fund the clinical trials, commercial and regulatory activities in 25 Asian countries, including Greater China (PRC Mainland China, Hong Kong, Macau, Taiwan), Thailand, Vietnam, Indonesia, Philippines and Singapore.
General Electric's (GE) Aviation segment's results in second-quarter 2019 will likely gain from rising popularity of LEAP engines. The Renewable Energy segment's results might be beneficial too.
General Electric's (GE) Power segment is likely to continue dealing with internal and external challenges. The reorganization plan might infuse some strength.
A look at the shareholders of HC2 Holdings, Inc. (NYSE:HCHC) can tell us which group is most powerful. Institutions...
NEW YORK, July 25, 2019 -- HC2 Holdings, Inc. (NYSE:HCHC), a diversified holding company, announced today that it will release its financial results for the second quarter 2019.
Carlisle (CSL) is likely to benefit from its strong foothold in non-residential construction market and strength in aerospace and defense markets.
HC2 Holdings (HCHC) is a diversified holding company that seeks opportunities to acquire and grow businesses that can generate long-term sustainable free cash flow and attractive returns, asserts low-priced stock expert Faris Sleem, editor of The Bowser Report.
HC2 Holdings, Inc. (“HC2” or the “Company”) (HCHC), a diversified holding company, announced today that its energy portfolio company American Natural Gas (“ANG”) has acquired ampCNG, a natural gas fuel provider, for $41 million. ANG is funding the acquisition through a combination of cash and the issuance of debt and preferred shares at the portfolio company level.
The transaction gives American Natural Gas a presence in the Southeast and expands its footprint of natural gas fueling stations in Texas, Indiana and Ohio.
R2 Dermatology (“R2”) announced today that it has entered into an exclusive distribution agreement with China’s Huadong Medicine Company Limited (“Huadong”) for the Asia-Pacific Region. R2 Dermatology was founded in late 2014 by Pansend Life Sciences (a subsidiary of HC2 Holdings, Inc.) and Blossom Innovations. Since inception, R2 has generated substantial safety and efficacy studies in several multi-center clinical studies both in North America and Asia. In addition, R2 has received two US FDA 510(k) clearances for its clinical stage devices.
R2 Dermatology Products to be Commercialized and Distributed by Huadong Medicine Company Limited NEW YORK, June 13, 2019 -- HC2 Holdings, Inc. (“HC2”) (NYSE: HCHC), a.
Carlisle's (CSL) solid foothold in non-residential construction market and strength in aerospace and defense markets are likely to prove conducive to its performance.